IDRS Labs seeks emergency nod for plant-based drug against Long Covid

August 29, 2022 | Monday | News

Completion of clinical development of Sodium Copper Chlorophyllin was done with multiple agencies

Image Credit: Shutterstock

Image Credit: Shutterstock

Bhabha Atomic Research Centre (BARC), Advanced Centre for Treatment, Research and Education in Cancer - Tata Memorial Centre (ACTREC-TMC) and IDRS Labs (IDRS), Bengaluru have announced the completion of Phase II clinical trial of Sodium Copper Chlorophyllin 750 mg tablets.

The phase II clinical trial was a multi-centre, randomised, open label, controlled trial of sodium-copper-chlorophyllin given along with treatment of physician’s choice versus treatment of physician’s choice in asymptomatic or mildly symptomatic patients with COVID-19.

A tripartite Memorandum of Agreement was signed among BARC, ACTREC-TMC and IDRS to develop Chlorophyllin against COVID-19 disease and other indications. The dossier is filed for 'Emergency Use Authorization (EUA)' for the treatment of SARS-CoV-2 Infection (COVID-19) by IDRS to the Drug Controller General of India (DCGI) as stated by Shivkumar Madki, Co-founder and MD, IDRS Labs.

Dr Sudeep Gupta, Director, ACTREC - Navi Mumbai, who was instrumental in designing the phase II clinical trial of Sodium Copper Chlorophyllin, observed that chlorophyllin’s ability to demonstrate anti-SARS-CoV-2 and immunomodulatory activity across model systems, combined with its excellent safety profile, makes it a possible candidate for prophylaxis against long-COVID.

Comments

× Your session has expired. Please click here to Sign-in or Sign-up

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy